STRATA Skin Sciences Files 8-K for Regulation FD Disclosure

TL;DR

**STRATA Skin Sciences just dropped an 8-K, likely sharing some news that could move the stock, so keep an eye out!**

AI Summary

STRATA Skin Sciences, Inc. filed an 8-K on February 26, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 26, 2024. The company, incorporated in Delaware with IRS Employer Identification No. 13-3986004, maintains its principal executive offices at 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044.

Why It Matters

This filing ensures transparency by publicly disclosing information that may be material to investors, preventing selective disclosure and maintaining fair markets.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure filing and does not inherently indicate a high-risk event.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• Delaware (company) — State of Incorporation
• 13-3986004 (dollar_amount) — I.R.S. Employer Identification No.
• 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044 (company) — Address of Principal Executive Offices
• 215-619-3200 (dollar_amount) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ

Filing Documents

• ef20022417_8k.htm (8-K) — 28KB
• ef20022417_ex99-1.htm (EX-99.1) — 11KB
• image00001.jpg (GRAPHIC) — 2KB
• 0001140361-24-009499.txt ( ) — 182KB
• sskn-20240226.xsd (EX-101.SCH) — 4KB
• sskn-20240226_lab.xml (EX-101.LAB) — 21KB
• sskn-20240226_pre.xml (EX-101.PRE) — 16KB
• ef20022417_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On February 26, 2024, STRATA Skin Sciences, Inc. announced that it had entered into Amendment No. 4 to Credit and Security Agreement among MidCap Financial Trust, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022, September 6, 2022 and June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: 99.1 Press release, dated February 20, 204, of STRATA Skin Sciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: February 26, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR